Encouraging data were presented on GenVec's respiratory syncytial virus (RSV) vaccine program demonstrating preclinical proof-of-concept findings generated in multiple animal models at the National Institutes of Health (NIH) and GenVec.
The data show sustained production of neutralizing antibodies and the lack of immunological adverse events linked to prior unsuccessful RSV vaccine approaches.